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Diabetes mellitus (DM) is a metabolic disease characterized by chronic hyperglycaemia; this 
condition is caused by lack of insulin secretion (Type 1) and/or insulin resistance (Type 2). In 
diabetic patients; carbohydrate, protein and lipid metabolism is disturbed due to the lack of 
the body’s ability to utilise glucose efficiently. Management of type 1 diabetes involves 
insulin therapy which may be inconvenient for patients. Therefore alternative methods for 
management of type 1 diabetes involving medicinal products are being investigated. This 
study is aimed at investigating the effect of OA on markers of lipid metabolism and on 
proteins of the insulin signalling pathway in Type 1 diabetic rats as this plant product has 
anti-hyperglycaemic effects. Male Sprague-Dawley rats were divided into two groups 
(diabetic and normal). In both groups the rats were further divided into four groups and 
assigned to treatment as follows: vehicle, insulin, OA and OA plus insulin. Oral glucose 
tolerance test was performed in fasted and non-fasted diabetic rats for 2 hours. In acute 
studies the effect OA following treatment of rats was evaluated at 15, 30 and 60 minutes. In 
sub-chronic studies rats were treated daily for 14 days. OA did not improve glucose tolerance 
in diabetic rats after 2 hours of administration. However, it enhanced blood glucose lowering 
effect of insulin and this was statistically significant in fasted rats. In acute studies OA 
enhanced the effect of insulin in normal and diabetic animals as AKT phosphorylation was 
increased when insulin was used in combination with OA. OA reduced the expression and 
activity of HSL in liver tissue after 14 days of treatment in both normal and diabetic rats. In 
adipose tissue, OA reduced the expression of HSL in diabetic rats. However, OA alone did 
not reduce the activity of HSL but when it was combined with insulin, a reduction of HSL 
activity was observed. OA administration had no significant effect on TGA and HDL-c levels 
but significantly (p < 0.05) reduced total cholesterol and LDL-c in diabetic rats. It had no 
significant effect on total cholesterol, and increased LDL-c levels in normal rats. Serum AST 
and ALT levels in diabetic rats were reduced by OA administration but this reduction was not 
statistically significant. The results of this study suggest that OA enhances the hypoglycaemic 
effect of insulin, improves lipid profile and possesses hepatoprotective effects. Lastly, OA 
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Diabetes mellitus (DM) is a condition characterized by hyperglycaemia and increased risk of 
cardiovascular disease. In diabetic patients lipid metabolism is impaired due to the lack of the 
body’s ability to utilize glucose efficiently. DM is associated with increased plasma 
cholesterol and triglyceride concentrations, which may lead to the development and 
progression of micro and macro vascular complications such as neuropathy, nephropathy, 
cardiovascular and cerebrovascular diseases. Management of DM involves the use of 
synthetic hypoglycaemic agents such sulphonylureas, biguanides, α-glucosidase inhibitors 
and thiazolidinediones. However, insulin has remained the primary means of treating this 
disorder. Medicinal plants such as Ficus thonningii and Syzygium cordatum have been 
reported to have hypoglycaemic effect in normal hosts. Efforts have also gone into isolating 
bioactive agents by which these medicinal plants lower blood glucose. These bioactive agents 
include triterpenes-like oleanolic acid (3ß-hydroxy-olea-12-en-28-oic acid, OA), which has 
been shown to have hypoglycaemic effects. There are various mechanisms by which OA can 
exert its hypoglycaemic effect such as the retardation of glucose absorption across the 
gastrointestinal membrane. Some studies have shown that OA increases glycogen synthesis in 
diabetic rats and this hypoglycaemic effect has also been observed with insulin treatment. 
This compound may therefore exert its effects via insulin signalling pathway. There is 
evidence which suggests that OA exerts its hypoglycaemic effect by activation of some 
proteins involved in the insulin signalling pathway. Recent studies have shown that OA 
increases phosphorylation of AKT in type 2 diabetic mice while some studies show that it 
enhances the activity of insulin tyrosine phosphorylation in cell lines. Of importance in this 
study is to investigate whether orally delivered OA affects lipid metabolism via the insulin 
signalling pathway in adipose tissue and liver in Type1 diabetes in which insulin is absent. 
The study will also assess whether OA delivered orally has any toxic effect on liver by 









1.1 Diabetes mellitus 
Diabetes mellitus (DM) is a condition characterized by hyperglycaemia and increased risk of 
cardiovascular disease, which is a major cause of death and disability in most countries (Ai et 
al. 2009). The incidence rate of DM is increasing with increasing levels of obesity and also 
with aging of the general population over the world (Kim et al. 2008). Currently, an 
estimated 220 million people worldwide have diabetes and this will increase to 300 million 
by 2025 (Li et al. 2005; Kondeti et al. 2010). The most common types of diabetes mellitus 
are type 1, type 2 and gestational diabetes. Type 1 diabetes is due to pancreatic β cell 
destruction that results in insulin deficiency (insulin-dependent diabetes mellitus). Type 2 
diabetes mellitus (non-insulin dependent diabetes mellitus) is the more prevalent of the two 
types of diabetes and is associated with both impaired insulin secretion and insulin resistance 
caused by a high calorie-nutrition and obesity. Globally, type 2 diabetes accounts for greater 
than 90% of the diabetes cases (Kim et al. 2008). Gestational diabetes mellitus is common 
amongst pregnant women due to insulin resistance (Schoenfelder et al. 2006). In diabetic 
patients lipid metabolism is altered due to the lack of the body’s ability to utilize glucose 
efficiently resulting in a disease state referred to as dyslipidaemia. In type 1 diabetes, tight 
glucose regulation usually corrects dyslipidaemia. However, in type 2 diabetes tight 
regulation or reduction of blood glucose does not correct dyslipidaemia (Papadakis et al. 
2001). Most of lipid disorders are associated with insulin resistance and failure of suppression 
of hormone-sensitive lipase in adipose tissue which leads to increased hepatic VLDL 
production and increased TG levels (Papadakis et al. 2001; Ai et al. 2009; Sorenson et al. 
2009). 
 
1.2 Role of lipoproteins in lipid homeostasis 
Lipoproteins are spherical particles composed of a central core of non-polar lipids and a 
surface monolayer of phospholipids, free cholesterol and apolipoproteins; and their function 
is to transport non-water soluble cholesterol and triglyceride in plasma (Koren et al. 1996; 
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Verges, 2009). Lipoproteins differ in their content of proteins and lipids and are classified 
according to their density as chylomicrons, very low-density lipoprotein (VLDL), 
intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) (Chung and Wasan, 2004). They are also classified based on their 
apolipoprotein content on their surface which governs the fate of the particle (Koren et al. 




Figure 1: Lipoprotein metabolism. Lipoprotein lipase (LPL); very low-density lipoprotein (VLDL); 
intermediate lipoprotein (IDL); low-density lipoprotein (LDL); high-density lipoprotein (HDL); HL: 
hepatic lipase; cholesteryl ester transfer protein (CETP); lecithin-cholesterol acyl transferase (LCAT); 
B/E receptor (B/E rec.); LDL receptor related protein (LRP); free fatty acids(FFA); cholesterol (Chol); 
triacylglycerol (TG); phospholipids(PL); apolipoprotein (Apo); cholesterol esters (CE); ATP binding 






Chylomicrons are the largest of the lipoprotein particles which are responsible for the 
transport of dietary triacylglycerol and cholesterol. They are composed of 85-90% 
triglyceride and cholesterol esters which are repackaged with apoB-48, apoA and 
phospholipids within the enterocytes (Chung and Wasan, 2004). Chylomicrons are then 
secreted by the intestinal mucosa into the lymphatic circulation before entering the 
bloodstream (Chung and Wasan, 2004; Verges, 2009). In the systemic circulation, they 
acquire cholesterol ester as well as apoC and apoE from HDL (Verges, 2009). The presence 
of apoC allows the particle to be recognised by the lipoprotein lipase (LPL) within the 
capillary beds of skeletal muscle and adipose tissue (Chung and Wasan, 2004). As a result, 
the triacylglycerols of chylomicrons are hydrolysed, releasing free fatty acids which are 
absorbed by nearby tissues for energy production and storage (Chung and Wasan, 2004). 
Residual particle known as chylomicron remnants return to the circulation and get cleared by 
the liver through receptor-mediated endocytosis; receptors on the surface of hepatocytes 
recognize apoE of the chylomicron remnant (Verges, 2009). 
 
1.2.2 Very-low-density lipoprotein 
VLDLs are triglyceride-rich plasma lipoprotein whose main function is to deliver lipids, 
mainly triglyceride from the liver to peripheral tissues (Barakat et al. 1996; Chung and 
Wasan, 2004; Verges, 2009). The lipid and protein components are synthesized in the liver, 
with apolipoproteins B100, C and E being the major protein components. Fatty acids used in 
triglyceride and phospholipid synthesis are derived from non-esterified fatty acids in the 
plasma, de novo synthesis from acetyl CoA and from hydrolysis of the lipids returned to the 
liver by other lipoproteins (Barakat et al. 1996). Triglyceride synthesis in the liver is 
influenced by insulin and glucagon levels and glycogen content in the liver (Barakat et al. 
1996). In blood VLDL acquires cholesterol esters; apoC and apoE transferred from HDL to 
become mature VLDL particles (Chung and Wasan, 2004).These mature particles are 
hydrolysed by lipoprotein lipase (LPL) into VLDL remnants releasing apoE and apoC from 
the surface coat and transferring them back to HDL (Barakat et al. 1996; Chung and Wasan, 
2004). This metabolic cascade leads to the formation of intermediate density lipoprotein 
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(IDL) particles, which can be removed from the circulation through interaction with the LDL 
receptor on hepatocytes or further metabolised to form LDL (Barakat et al. 1996; Verges, 
2009). 
1.2.3 Low-density lipoprotein 
LDLs are plasma lipoproteins which are main carriers of unesterified and esterified 
cholesterol to tissues where they are internalized through the LDL-mediated pathway 
(Barakat et al. 1996). The cholesterol in the core of the LDL particle is esterified to fatty 
acids and this is delivered in a form of cholesterol esters (Chung and Wasan, 2004). LDL in 
the plasma arises from VLDL after it has lost the core triacylglycerides and some of the 
surface proteins except apoB-100 (Salter and Brindley, 1988; Barakat et al. 1996). ApoB-
100s are essential for recognition of the LDL particle to its receptor and subsequent uptake 
into cells (Salter and Brindley, 1988). The majority of LDL is removed by the liver through 
the LDL receptor and other non-receptor-mediated pathways (Salter and Brindley, 1988). 
The homeostasis of cholesterol concentration is due to three regulatory elements: 3-hydroxy-
3-methylglutaryl-CoA reductase (HMG-CoA), the rate-limiting enzyme in cholesterol 
biosynthesis; acyl-CoA: cholesterol O-acyltransferase (ACAT) which re-esterifies excess 
intracellular cholesterol for storage; and expression of LDL receptors on the cell surface 
(Salter and Brindley, 1988). Furthermore, the regulation of serum LDL depends on the 
quantity of VLDL produced by the liver which then becomes converted to LDL and the 
proportion of VLDL remnants (IDL) that are removed by the LDL receptor in the liver 
(Salter and Brindley, 1988; Barakat et al. 1996). Therefore, the LDL receptor is the critical 
regulator of serum LDL concentrations both in rate of formation and rate of clearance of LDL 
particles. 
 
1.2.4 High-density lipoprotein 
HDL are heterogeneous lipoproteins containing several subclasses of lipoproteins, mainly 
HDL2 and HDL3 present in most species (Salter and Brindley, 1988). HDL is responsible for 
removal of cholesterol from peripheral tissues and for subsequent transport to the liver 
through a process known as ‘reverse cholesterol’ transport (Salter and Brindley, 1988; Chung 
and Wasan, 2004; Verges, 2009). HDL particles are secreted by the hepatocytes as small, 
lipid-poor lipoproteins that contain mostly apoA-I and receive phospholipids, apoCs and 
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apoE from chylomicrons and VLDL in the circulation (Chung and Wasan, 2004; Verges, 
2009). Circulating HDL receives free cholesterol and phospholipids through the ATP-binding 
cassette A1 transporter from peripheral cells; this allows the transfer of free cholesterol and 
phospholipids from the cell cytoplasm to HDL particles (Barter et al. 2003). Within the HDL 
particles, free cholesterol is esterified by lecithin cholesterol acyltransferase (LCAT), which 
leads to the formation of HDL3 particles (Chung and Wasan, 2004). Fusion of two HDL3 
particles leads to formation of one large HDL2 particle. HDL2 cholesterol ester-rich 
lipoproteins are degraded by lipases, leading to the formation of HDL remnant particles. 
These remnant particles get cleared by the liver after being recognised by scavenger receptors 
(Verges, 2009).  
 
1.3 Lipid metabolism in diabetes 
Alteration in lipid metabolism is more common in type 2 diabetes than in type 1 diabetes.  
The major abnormalities are high levels of TGAs, which are associated with reduced levels of 
HDL cholesterol (Batteridge, 1996; Maahs et al. 2005). Increased levels of TGAs also result 
in increased levels of circulating LDL cholesterol since both are derived from VLDL. High 
levels of circulating LDL cholesterol have been shown to reduce flow-mediated dilation of 
arterial vessels, resulting in endothelial dysfunction (Stratmann and Tschoepe, 2009) (refer to 
Fig 2). Endothelial dysfunction is considered as the early step in the development of 
atherosclerosis, and recruits inflammatory cells into the vessel wall and initiates plaque 
formation (Mehta et al. 2006). A dysfunctional endothelium facilitates oxidation of 
circulating LDL-c, monocyte entry, vasoconstriction, deposition of extracellular matrix and 
internalisation via expression of various adhesion molecules (Padakakis et al. 2001). 
Intravascular accumulation of LDL leads to its oxidation and induction of inflammation 
within the intima. Macrophage colony-stimulating factor causes monocytes to differentiate 
into macrophages which subsequently become foam cells which break down to form fatty 
streaks. These fatty streaks provide the beginnings of lipid core of the mature atherosclerotic 
plaque (Stratmann and Tschoepe, 2009). HDL is able to collect cholesterol from foam cells 
and transport it out of the artery wall for catabolism and excretion and it has antioxidant 
enzymes such as pareoxonase-1, which can inactivate pro-inflammatory phospholipids 
(Stratmann and Tschoepe, 2009). However, in diabetes mellitus there are low levels of 
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circulating HDL which perpetuates the formation of the plaque which leads to development 
of cardiovascular diseases (Williams, 2012). 
 
 
Figure 2: Postulated steps in atherosclerosis. Oxidised low-density lipoproteins (ox-LDL); Low-density 
lipoprotein cholesterol (LDL-c); leptin-like oxLDL receptor (LOX-1); Macrophage colony-stimulating 
factor (M-CSF); intracellular adhesion molecule (ICAM); Angiotensin II (Ang II); Monocyte 
chemoattractant protein-1 (MCP-1); Vascular cell adhesion molecule (VCAM); Matrix 
metalloproteinases (MMP) (Adapted from Mehta et al. 2006). 
 
 
1.4 Management of diabetes mellitus 
The main aim of treating diabetes is to lower elevated blood glucose levels to normal levels. 
Insulin, a hormone responsible for lowering blood glucose has been the primary means of 
treating diabetes since it discovery in 1922 (De Meytes, 2004). There are also different 
hypoglycaemic agents such as biguanides, sulphonylureas, thiazolidinediones and alpha-
glucosidase inhibitors that have been developed to manage diabetes (Oiknine and Mooradian, 
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2003). Some of these hypoglycaemic agents are used in combination with insulin for 
maximum control of blood glucose. These hypoglycaemic agents use different mechanisms to 
lower blood glucose (Refer to Figure 3). 
  
 




The first oral agents to be used for treatment of type 2 diabetes were the sulphonylureas 
(SFU) and were found to exert their hypoglycaemic effect by directly stimulating pancreatic 
β-cells (Anselmino, 2009; Donner, 2006). SFU bind to ATP-sensitive potassium channels 
and inhibit potassium efflux resulting in calcium influx through calcium channels and the rise 
in intra cytosolic calcium concentrations triggers the release of insulin (Anselmino, 2009; 
Oiknine and Mooradian, 2003). Thus SFUs increase basal and postprandial insulin secretion. 
8 
 
Administration of SFUs has been shown to lead to a decrease in glycosylated heamoglobin of 
1% to 2% (Braunstein, 2003). However, these agents have been associated with weight gain 
and hypoglycaemia due to overstimulation of pancreatic β-cells and secondary failure due to 
beta cell exhaustion has been reported (Oiknine and Mooradian, 2003). There are also 
meglitinides drugs which have a SFU-like mechanism of action but they target a different 
binding site on pancreatic β-cells leading to a similar events triggering insulin release 
(Anselmino, 2009; Donner, 2006). The classes of drugs mentioned above are mostly used in 
type 2 diabetes. However, there are also commercially available drugs available for 
management or treatment of both type 2 and type1 diabetes. 
 
1.4.2 Biguanides 
Currently, metformin is the only drug in this class available. The presence of insulin is 
necessary for this class of drugs to exert their hypoglycaemic effects (Anselmino, 2009; 
Donner, 2006). The molecular bases of how metformin decreases blood glucose are not well 
understood. It has been speculated that it enhances hepatic insulin response via inhibition of 
gluconeogenesis and to a lesser extent increasing the insulin sensitivity of peripheral tissues 
such as a muscle (Anselmino, 2009; Oiknine and Mooradian, 2003). The other effects of this 
drug include decrease appetite, food absorption and reduction in low-density lipoprotein 
(Setter et al. 2003). This drug is recommended in all patients with mild hyperglycaemia and 
overweight as it has been shown to decrease body weight at high doses (Anselmino, 2009). 
Clinical trials have demonstrated that metformin therapy reduces the risk of microvascular 
complication. However, side effects such as nausea and bloating have been reported (Oiknine 
and Mooradian, 2003). 
 
1.4.3 Thiazolidinediones 
Rosiglitazone and pioglitazone are representative of the thiazolidinediones (TZDs), which are 
a class of hypoglycaemic agents that decrease insulin resistance and improve insulin action 
(Braunstein, 2003).The mechanism of action of these drugs, like alpha-glucosidase inhibitors 
does not involve insulin secretion which makes them better candidates for type1 diabetes 
treatment (Oiknine and Mooradian, 2003). TZDs enhance glucose uptake and utilization in 
peripheral tissues, especially skeletal muscle, liver and adipose tissue (Braunstein, 2003; 
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Oiknine and Mooradian, 2003). TZDs bind to and activate peroxisomal proliferator-activated 
receptor-gamma receptors, the activated receptors bind to DNA and increase transcriptional 
modulation of genes involved in carbohydrate and lipid metabolism (Oiknine and Mooradian, 
2003). Some of the drugs in this class have been reported to increase HDL cholesterol and 
decrease triglyceride levels however their drawback is increasing LDL cholesterol which is 
associated with increased risk of coronary heart disease (Braunstein, 2003; Oiknine and 
Mooradian, 2003). TZDs are also associated with adverse effects such as weight gain and 
stimulation of adipogenesis (Setter et al. 2003).  
 
1.4.4 α-Glucosidase inhibitors 
One of the therapeutic approaches for preventing DM is to retard absorption of glucose via 
inhibition of α-glucosidase, a carbohydrate-hydrolysing enzyme in the digestive organ 
(Oiknine and Mooradian, 2003). α-Glucosidase inhibitors (AGIs) reversibly inhibit α-
glucosidases, such as maltase and sucrase in the intestine, thus delaying the absorption of 
sugar from the gut and suppressing postprandial hyperglycaemia (Shai et al. 2010). α-
Glucosidase inhibitors have other benefits, such as reducing trigycerides and postprandial 
insulin levels (Jong-Anurakkun et al. 2007). Acarbose and maglitol are known examples of 
competitive inhibitors of α-glucosidases. Some medicinal plants such as Dillenia indica, 
Cratoxylum mangayi, Alstonia scholaris, and Cassia abbreviata crude extracts have been 
shown to have an inhibitory effect on maltase and sucrase (Jong-Anurakkun et al. 2007; Shai 
et al. 2010).   
 
1.4.5 Insulin 
Insulin is the primary hormone responsible for controlling the transport, utilisation and 
storage of glucose in the body. Insulin is secreted by beta-cells of the pancreatic islets as a 
single chain, known as proinsulin (Pessin and Saltiel, 2000; Varshosaz, 2007). Proteolysis of 
proinsulin results in the removal of certain amino acids in the proinsulin and the connecting 
C-peptide providing the biological active polypeptide insulin (De Meytes, 2004; Varshosaz, 
2007). This biologically active form of insulin is a monomer consisting of two chains, an A 
chain of 21 amino acids and a B chain of 30 amino acids linked by disulfide bonds (De 
Meytes, 2004). Insulin was first successfully isolated by Frederick Banting and Charles Best 
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in 1921 and was introduced into clinical practice in 1922, since then it has remained the 
primary means of treating type 1 diabetes (De Meytes, 2004; Varshosaz, 2007; Owens et al. 
2003). Administration of insulin in the form of subcutaneous (s.c) injection has been the basis 
of insulin therapy since its introduction.  Insulin formulated for s.c injection reaches its 
maximum activity at 2 to 3 hours following injection and the duration effect is said to be 6 to 
8 hours (Varshosaz, 2007). Therefore treatment of diabetes with insulin requires regular 
injection of insulin and due to the inconvenience injections of insulin; various approaches 
have been attempted to administer insulin in non-injectable routes (Owens et al. 2003).  
Insulin regulates glucose homeostasis in various ways, increasing the rate of glucose uptake 
primarily in skeletal muscle and adipose tissue and reducing hepatic glucose output via 
decreased gluconeogenesis and glycogenolysis (Pessin and Saltiel, 2000). In muscle and 
adipose tissue, insulin stimulates translocation of the glucose transporter GLUT4 to the 
surface thus clearing the circulating glucose. Insulin also affects lipid metabolism by 
increasing lipid synthesis in liver and adipose tissue, and inhibiting lipolysis in muscle and 
adipose tissue (Pessin and Saltiel, 2000). Patients on insulin treatment have shown non-
compliance to medication due to discomfort of subcutaneous injection of insulin and insulin 
is not widely available in underdeveloped countries. On the other hand, plants which possess 
hypoglycaemic effect are available to all communities and are affordable. 
 
1.4.6 Medicinal plant extracts 
There has been a need to develop alternative methods to treat or manage diabetes such as 
medicinal plants due to their affordability by resource-poor people. Various medicinal plants 
with anti-diabetic properties have been used for several years worldwide (Drover et al. 2002; 
Ruzaidi et al. 2005; Musabayane et al. 2005). Prevalence of DM in India is estimated to be 1-
5% with complications being the main cause of morbidity and mortality (Drover et al. 2002). 
Various indigenous plants have been used in the treatment of DM since the 6
th
 century. These 
medicinal plants used in India include: Aleo barbadensis, Artemisia pallens, Azadirachta 
indica, and Morus alba and all have been shown to exert hypoglycaemic effect through 
different mechanisms (Drover et al. 2002). Ruzaidi et al. (2005) investigated the effect of 
Malaysian cocoa extract on blood glucose levels and lipid profiles in streptozotocin-induced 
diabetic rats. This extract was reported to increase body weight and decrease blood glucose 
concentrations through regeneration of β-cells damaged by streptozotocin (STZ) (Ruzaidi et 
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al. 2005). Cocoa extract also improved lipid profiles by decreasing total cholesterol and 
triglyceride levels in hyperglycaemic group and these lipids have previously been shown to 
contribute to the development of vascular disease (Ruzaidi et al. 2005). The cocoa extract 
also increased levels of HDL cholesterol which suggest that it has some protective effect 
against hypercholesterolemia risks in diabetes (Ruzaidi et al. 2005). However, the exact 
mechanisms by which this extract lower blood glucose and improve lipid profile need further 
studies. Some medicinal plants have been shown to have effects on carbohydrate metabolic 
enzymes (Kondeti et al. 2010; Ngubane et al. 2010). 
 
Pterocarpus santalinus bark has been used for treatment of diabetes and it has also been used 
for treatment of skin irritation, helminths, ulcers and eye disease (Kondeti et al. 2010). The 
effect of bioactive agent of Pterocarpus santalinus bark, ethyl acetate: methanol extract has 
been shown to decrease blood glucose concentration by improving insulin secretion, 
increasing liver glycogen levels in diabetic rats and enhancing hepatic hexokinase activity 
(Kondeti et al. 2010). Hexokinase is an insulin dependent key enzyme in the glycolytic 
pathway. Increased activity of hexokinase causes the increase in glycolysis, glycogenesis and 
glucose utilisation for energy production (Kondeti et al. 2010; Ngubane et al. 2010). In 
diabetic patients, there is increased activity of gluconeogenic enzymes due to activation or 
increased synthesis of the enzymes contributing to increased hepatic glucose production. 
Activation of gluconeogenic enzymes may also be due to decreased insulin levels given that 
under normal conditions, insulin suppresses these enzymes (Kondeti et al. 2010). Treatment 
of diabetic rats with Pterocarpus santalinus extract reduced the activity of these enzymes and 
this reduction can result in decreased concentration of glucose in the blood (Kondeti et al. 
2010). This plant extract also increases glucose utilisation by the pentose phosphate pathway 
by increasing the activity of glucose-6-phosphate dehydrogenase (Kondeti et al. 2010).  
 
Plants of the genus Syzygium have been used in the treatment of diabetes mellitus in rural 
communities of Asia, South America and South Africa. Syzygium cordatum leaf extract has 
been shown to decrease plasma glucose levels and hepatic glycogen in STZ-induced diabetic 
rats (Musabayane et al. 2005). Hypoglycaemic effect observed with Syzygium cordatum leaf 
extract did not involve insulin secretion since pancreatic β-cells were destroyed with STZ and 
this indicated that the extract may have increased glucose uptake via other mechanisms 
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(Musabayane et al. 2005). Spectroscopic analysis of Syzygium cordatum leaf extract has been 
shown to have oleanolic acid (OA), ursolic acid, methyl maslinate and methyl corosolate 










Figure 4: Chemical structure of oleanolic acid (International Union of Pure and Applied Chemistry, 
IUPAC).  
 
Oleanolic acid (OA) (3β-hydroxy-olea-12-en-28-oic acid) is triterpene found in a variety of 
plant species, this compound and its isomer ursolic acid have been found to have numerous 
biological properties with therapeutic potential. These compounds have been reported to 
possess anti-inflammatory, anti-tumourigenic, anti-viral and hepatoprotective effects in a 
dose dependant manner (Liu, 1995; Gao et al. 2009). Recently, OA has been shown to 
possess antimycobacterial activity against six drug sensitive and drug resistant strains and a 
synergistic effect was observed when OA was used in combination with isoniazid, rifampicin 
or ethambutol (Ge et al. 2010). Teodoro et al. (2008) reported that OA exerts its 
hypoglycaemic effects by directly stimulating pancreatic β-cells to improve insulin secretion 
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in isolated INSI 832/13 pancreatic β-cells. However, it was not shown whether OA uses the 
same mechanism to lower blood glucose in vivo. Great effort has gone into studying the 
mechanism by which OA exerts its hypoglycaemic effect. Recent studies done on plant-
derived OA have given evidence that its hypoglycaemic effect does not involve insulin 
secretion and this bioactive agent has been shown to have a positive effect on kidney function 
(Mapanga et al. 2009). For bioactive agents to be used for diabetes treatment, they should 
have a positive effect on complications associated with DM. Mapanga et al. (2009) assessed 
the effect of S. cordatum leaf derived OA in renal function by evaluating its ability to 
increase urinary sodium outputs parameters and creatine clearance of STZ-induced diabetic 
rats as a measure of glomerular filtration rates, which determines the degree of electrolytes 
retention. In acute and chronic studies, OA significantly increased urinary sodium output as it 
increased glomerular filtration rate in STZ-induced diabetic rats in comparison to non-
diabetic rats and this compound also decreased blood glucose and urinary glucose in STZ-
induced diabetic rats (Mapanga et al. 2009). Recent studies have shown that OA increased 
hepatic and muscle glycogen concentrations of both non-diabetic and STZ-induced diabetic 
rats, and an additive effect was observed when OA was combined with insulin which showed 
that OA has the ability to exert it hypoglycaemic effects by enhancing insulin effect 
(Ngubane et al. 2010). The ability of OA to stimulate muscle glycogen synthesis in diabetic 
rats indicates that it has insulin mimetic effects as muscle glycogen is dependent on insulin. 
 
OA has antioxidant activity as it has been shown to decrease malondialdehyde and increase 
superoxide dismutase and glutathione peroxidase activities of the liver and kidney in alloxan 
–induced diabetic rats (Gao et al. 2009). These enzymes function together to scavenge free 
oxygen species which can cause tissue damage. This compound has also been shown to 
reduce levels of serum cholesterol, triacyglycerols, LDL-c and increases HDL-c in type 2 
diabetic rats; this could reduce the risk of diabetic patients developing cardiovascular diseases 
(Gao et al. 2009; de Melo et al. 2010). In diabetes, there is an increase in serum levels of 
enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and 
alkaline phosphatase which are found elevated when there is hepatic damage. However, 
treatment of type 2 diabetic rats with OA reduces the levels of these enzymes (Gao et al. 
2009; Ge et al. 2010). Jung et al. (2007) have shown that OA and UA reduces 
hyperglycaemia by enhancing the activity of insulin on tyrosine phosphorylation on insulin 
sensitive cell lines with the latter compound showing greatest enhancement and also 
enhancing the effect of insulin on GLUT 4 translocation. This evidence suggests that these 
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compounds may act as insulin receptor activators. Other mechanism by which OA reduces 
hyperglycaemia is by inhibition of α-glucosidase, an enzyme involved in the absorption of 
glucose from the small intestine (Ali et al. 2002). OA and UA diminish renal aldose 
reductase and glycoxalase activity, and down regulates their mRNA expression in diabetic 
rats (Wang et al. 2010). This is beneficial to diabetic patients by preventing or delaying 
progression of diabetic nephropathy by reduction of advanced glycation end product (Wang 
et al. 2010). Recently OA has been shown to reverse hyperglycaemia in type 2 diabetic mice 
four weeks post treatment, indicating that it may be a potential drug for sustained control of 
hyperglycaemia (Zeng et al. 2012). This sustained control of hyperglycaemia was associated 
with suppression of gluconeogenesis in the liver which is mediated by the AKT/FoxO1 axis. 
FoxO1 is a key transcriptional factor regulating hepatic gluconeogenesis and its 
phosphorylation by AKT leads to its degradation. Therefore increased levels of 
phosphorylated AKT suppress the expression of glucose 6-phosphatase a key enzyme for 
hepatic glucose production (Zeng et al. 2012). Thus, literature evidence suggests that the 
hypoglycaemic effect of OA involves phosphorylation of some of the proteins of the insulin 
signalling pathway. 
 
1.5 Insulin signalling pathway 
Insulin receptor (IR) is a tetrameric protein which consists of two identical extracellular α-
subunits and two transmembrane β-subunits which have tyrosine kinase activity (Chung et al. 
2004; Jung et al. 2007; Daisy et al. 2009). In response to increased blood glucose levels 
insulin is secreted by pancreatic β-cells. Insulin binds to the α-subunit and causes 
conformational change and stimulation of the receptor kinase activity via auto-
phosphorylation of tyrosine residues in the β-subunits (Jung et al. 2007). The activated IR 
kinase phosphorylates substrate proteins, including the IRS family of proteins (Jung et al. 
2007). This triggers the activation of phosphatidylinositol-3 kinase (PI3K) kinase signalling 
cascade which is one of the earliest steps in the insulin signalling pathway (Jung et al. 2007). 
The end product of the PI3K cascade [phosphatidylinositol (3,4,5) trisphosphate] activates 
protein kinase B (AKT) which stimulates glucose uptake in skeletal muscle, adipocytes and 
cardiac muscle tissue via translocation of GLUT-4 vesicles to the plasma membrane (Jung et 
al. 2007; Daisy et al. 2009). Activated AKT also inhibit lipolysis via activation of 
phosphodiesterase 3B (PDE3B) which inhibits cAMP accumulation and this inhibition results 
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in down regulation of the hormone sensitive lipase (HSL) which is the key in fat breakdown 
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1.5.1 Insulin receptor substrate-1 
Insulin receptor substrate-1 (IRS-1) is a phospho-protein which has a molecular weight of 
~160-185 kDa and is a major substrate for insulin receptor kinase (Smith et al. 1996). IRSs 
(IRS-1 to IRS-4) contain pleckstrin homology (PH) domains, phosphotyrosine binding (PTB) 
domains at the amino-terminus, and several tyrosine phosphorylation sites at the carboxyl-
terminus (Ye et al. 2002). IRS proteins can dock on the intracellular domain of the IR and 
mediate its signalling. Activation of the IR leads to recruitment and phosphorylation of IRS 
proteins which in turn recruit and activate other downstream signalling molecules, such as 
Shc and src-homology 2 (SH2) domain-containing proteins, including PI-3 kinase (Ye et al. 
2002). IRS-1 is required in insulin stimulated mitogenesis and perhaps in insulin-stimulated 
glucose uptake (Smith et al. 1996). 
 
1.5.2 Phosphatidylinositol 3-kinase 
Phosphatidylinositol 3-kinases (PI3Ks) have been classified into three major subfamilies 
according to their structure and the substrate specificity. Class I PI3Ks are activated by cell 
surface receptors and consist of two subfamilies, Class IA and Class IB, based on the 
associated adaptors (Jiang and Liu, 2008). Class IA PI3Ks are composed of heterodimers of a 
p110 catalytic subunit and a p85 regulatory subunit. There are three different isoforms of 
p110 catalytic subunit: p110α, p110β and p110δ that are encoded by PIK3CA, PIK3CB and 
PIK3CD genes, respectively (Jiang and Liu, 2008). The p85 regulatory subunit also has three 
major isoforms: p85α, p85β and p55γ that are encoded by PIK3R1, PIK3R2 and PIK3R3 
genes, respectively (Jiang and Liu, 2008). The PIK3R1 gene codes for two shorter isoforms, 
p55α and p50α through alternative splicing. Class IB PI3Ks are composed of heterodimers of 
a p101 regulatory subunit and a p110γ catalytic subunit. There are two other p101 
homologues, p84 and p87PIKAP (PI3Kγ adaptor protein of 87 kDa). Class IA PI3Ks can be 
activated by receptor tyrosine kinases (RTKs), while Class IB PI3Ks by G-protein coupled 
receptors (GPCRs) (Donahue and Fruman, 2004). Phosphatidylinositol-3,4-bisphosphate 
[PI(3,4)P2] and phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] are the major products 
of class I PI3Ks generated from phosphatidylinositol-4,5-bisphosphate (Jiang and Liu, 2008; 





1.5.3 Akt/Protein kinase B 
 
Akt proteins, also known as protein kinases B (PKBs), comprises of 3 proteins, Akt 1, 2, and 
3 have emerged as central control nodes in the regulation of an array of fundamental cellular 
functions such as cell proliferation, survival and programmed cell death, glucose metabolism, 
ribosomal function, transcription, and cell migration via phosphorylation of a multitude of 
substrates (Shtilbans et al. 2008). The Akt (PKB) pathway is activated by 
phosphatidylinositol 3-kinase (PI3-K) in response to insulin, growth factors, cytokines and 
cell stress, causing the recruitment of Akt to the plasma membrane (Timmons et al. 2009). 
Phosphatidyl inositol-3 kinase converts phosphatidyl inositol-4,5-bisphosphate (PIP2) at the 
3′ position of the inositol ring to PIP3. The presence of PIP3 is required for activation of Akt, 
which occurs at the plasma membrane via Akt phosphorylation, mediated by 2 phosphatidyl 
inositol-3-phophate dependent kinases, PDK1, which phosphorylates Akt 1 at Serine (Ser) 
473 and PDK2, which phosphorylates Akt 1 at Threonine (Thr) 308. Phosphorylation at Thr 
309 and Ser 474 activates Akt 2 (Hay, 2011). Phosphorylation at Thr 305 activates Akt 3. 
Phosphorylated Akt dissociates from the membrane and phosphorylates phosphodiesterase in 
the cytosol (Shtilbans et al. 2008). 
  
1.5.4 Phosphodiesterase 3B 
 
Phosphodiesterase 3B (PDE3B) belongs to a super family of cAMP and cGMP degrading 
enzymes and is expressed in cells important for glucose and lipid metabolism such as 
adipocytes, hepatocytes and pancreatic β-cells (Nilsson et al. 2006, Degerman et al. 2011). 
The PDE3 family consist of two members, PDE3A and PDE3B (Zmuda-Trzebiatowska et al. 
2006, Chung et al. 2003). PDE3B role and regulation have been extensively studied in 
adipocytes where it has been demonstrated to have a key role in insulin-mediated inhibition 
of lipolysis. Insulin-induced phosphorylation and activation of PDE3B leads to increased 
hydrolysis of cAMP, lowering of protein kinase A (PKA) activity and thereby a decrease in 
PKA-dependent phosphorylation and activation of hormone sensitive lipase and lipolysis 
(Zmuda-Trzebiatowska et al. 2006). PDE3B has also been suggested to be involved in the 
regulation of insulin-induced glucose uptake, GLUT-4 translocation to the plasma membrane, 






1.5.5 Hormone sensitive lipase 
 
Hormone-sensitive lipase (HSL) is an intracellular neutral lipase that is highly expressed in 
adipose and steroidogenic tissues. The enzyme has broad substrate specificity, displaying 
hydrolytic activity against triacylglycerol, diacylglycerol and cholesteryl ester (Shen et al. 
2001). Observations from HSL-null mice have shown that HSL is responsible for 50% of the 
neutral triglyceride lipase activity and all of the neutral cholesteryl ester hydrolase activity in 
white adipose tissue. Thus HSL plays an important role in regulating lipolysis and the release 
of fatty acids from adipose tissue (Shen et al. 2001). Hydrolysis of adipocyte triacylglycerols 
occurs through three consecutive reactions and is catalysed by two enzymes: HSL and 
monoglyceride lipase. HSL alone catalyses the hydrolysis of triacylglycerols and 
diglycerides, whereas the participation of monoglyceride lipase is required to obtain complete 
hydrolysis of monoglycerides (Holm, 2003). 
 
Lipolytic stimuli increase lipolysis by activating adenylate cyclase and raising intracellular 
concentrations of cyclic AMP, with resultant activation of cyclic AMP-dependent protein 
kinase (PKA), which phosphorylates both perilipins and HSL. The phosphorylation of HSL is 
associated with an increase in hydrolytic activity of the enzyme and the translocation of HSL 
from the cytosol to the lipid droplet in some physiological settings (Shen et al. 2001; 
Greenberg et al. 2001). PKA has been shown to phosphorylate HSL at residues Ser563, 
Ser659, and Ser660, all of which reside in a150-amino acid stretch, termed the regulatory 
module. The regulatory module is found within the C-terminal domain of HSL, which also 
contains the catalytic triad (Holm, 2003; Greenberg et al. 2001). In vitro PKA 
phosphorylation of HSL can be monitored as an increased activity against triglyceride and 
cholesteryl ester substrates. In vivo, PKA phosphorylation is known to result in translocation 








Figure 6: Hormonal control of adipocyte hydrolysis. α- adrenergic receptors (α-AR); β - adrenergic 
receptors (β-AR); G-protein (G); Adenylate cyclase (AC); Extracellular-signal-regulated kinase 1/2 
(ERK1/2); cyclic adenosine mono-phosphate (cAMP); protein kinase A (PKA); 5’-AMP-activated protein 
kinase (5’AMPK); Hormone-sensitive lipase (HSL); Triglyceride (TG); Diglyceride (DG); Monoglyceride 




1.6 Justification of the study 
 
Previous studies have reported that the hypoglycaemic effects of Syzygium cordatum 
(Hochst.) [Myrtaceae] extracted mixtures of oleanolic acid (OA) and ursolic acid (UA) in 
streptozotocin-induced diabetic rats are in part mediated via increased hepatic glycogen 
synthesis (Musabayane et al.2005). There are other possible mechanisms by which OA can 
exert its hypoglycaemic effect such as the retardation of glucose absorption across the 
gastrointestinal membrane (Ali et al. 2002). Ngubane et al. (2010) have also shown that OA 
increases glycogen synthesis in diabetic rats and this hypoglycaemic effect has also been 
observed with insulin treatment. This compound may therefore exert its effects via insulin 
signalling pathway. There is literature evidence which suggests that OA exerts its 
hypoglycaemic effect by activation of some proteins involved in the insulin signalling 
pathway. Recent studies have shown that OA increases phosphorylation of AKT in type 2 
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diabetic mice (Zeng et al. 2012) while some studies have shown that it enhances the activity 
of insulin tyrosine phosphorylation in cell lines (Jung et al. 2007). Therefore this study will 
investigate whether OA exerts its hypoglycaemic effect by increasing phosphorylation of 
IRS-1, AKT and HSL in type 1 diabetic rats. The study will also assess changes in the 
expression of HSL over the treatment period. This compound has also been shown to reduce 
levels of serum cholesterol, triacylglycerols, LDL-c and increase HDL-c in diabetic rats, 
suggesting that it has antihyperlipidemic properties (Gao et al. 2009; de Melo et al. 2010). 
However, these studies were conducted over a long period of time and were done on type 2 
diabetic models. Therefore this study will also assess the effect of OA on lipids over a short 
period of time in type 1 diabetic rats. Diabetes is known to induce hepatic dysfunction which 
is evidenced by increase liver enzymes following its induction. This study will also 
investigate the effect of OA on aspartate aminotransferase (AST) and alanine 
































Male Sprague-Dawley rats (250-300g body weight) bred and housed in the Biomedical 
Research Unit (BRU) of University of KwaZulu–Natal were used in this study. The animals 
were maintained under standard laboratory conditions of constant temperature (22±2 °C), 12 
h light/dark cycles and had free access to water and standard rat chow (Meadows, 
Pietermaritzburg, South Africa). All experiments were performed with approval of the 
University of KwaZulu-Natal Research Ethics Committee guidelines for experimental 






All chemicals were of analytical grade and were purchased from Sigma Aldrich chemicals 
and Bio-Rad laboratories except for tween 80, chloroform, heptane, methanol and diethyl 
ether which were purchased from Merck, South Africa. Phosphorylated antibodies (pAKT 
Ser473 and pHSL Ser563) were obtained from Cell Signalling Technology, Laboratory 
Specialist Services cc, South Africa whereas non-phosphorylated HSL (ab45422) was 
purchased from ABCAM, Biocom Biotech, South Africa. Secondary antibodies: Goat anti-
rabbit IgG dylight 650 conjugated was purchased from Thermoscientific, Pierce 
Biotechnology (U.S.A) and anti-rabbit alkaline phosphatase conjugated IgG was obtained 
from Bio-Rad laboratories (S.A). Humalog kwikpen insulin from Lilly (S.A.), radioactively 
labelled cholesterol oleate [9,10-3H] from BIOTREND Chemikalien GmbH , Germany and 
oleanolic acid (OA) from Shaanxi King Stone Enterprise Company Ltd (China) were used in 







2.2.1 Dissolution of OA 
 
Three different concentrations of dimethyl sulphoxide (DMSO) [10 %; 30 %; 50 %] in 
physiological saline were used to determine the solubility of OA. 100 mg of OA was first 
suspended in different concentrations of DMSO and diluted down with saline in a glass vial, 
after vigorous stirring the vials were left undisturbed for 2 hours at room temperature. The 
suspension of OA was then assessed after the 2 hour incubation period. The concentration of 
DMSO that gave the best OA suspension was used in subsequent studies. 
 
2.2.2 Experimental design 
 
Male Sprague-Dawley rats were divided into two groups (diabetic and normal). In both 
groups the rats were further divided into four groups and assigned to treatment as follows:  
 
Group 1: Normal control (NC) treated with vehicle (50 % DMSO in saline) 
Group 2: Normal insulin (NI) treated with 4 unit/kg b.w. insulin 
Group 3: Normal OA (NO) treated with 80 mg/kg b.w. OA 
Group 4: Normal OA + insulin (NOI) treated with OA plus insulin 
 
Group 5: Diabetic control (DC) treated with vehicle (50 % DMSO in saline) 
Group 6: Diabetic insulin (DI) treated with 4 units/kg b.w insulin 
Group 7: Diabetic OA (DO) treated with 80 mg/kg b.w. OA 











2.2.3 Induction of diabetes mellitus 
 
Diabetes mellitus was induced as previously described by Daisy et al. (2009), male Sprague-
Dawley rats were given a single intraperitoneal injection of streptozotocin (STZ, 60 mg/kg) 
dissolved in cold freshly prepared 0.1 M citrate buffer (pH 4.5). Animals that exhibited blood 
glucose concentration of ≥18 mmol/L after one week were considered as stable diabetic 
animals and were used in the study. Control animals were injected with the vehicle citrate 
buffer. 
 
2.2.4 Oral glucose tolerance test  
 
The oral glucose tolerance test (OGTT) was performed on diabetic rats. Rats that were fasted 
overnight for 18 hours were divided into three groups of six animals each. Group 1: diabetic 
control; Group 2: diabetic rats treated with insulin; Group 3: diabetic rats treated with OA. 
Prior to the beginning of the experiment, blood was collected from the tip of the tail (time 0). 
And then rats in all groups were orally administered glucose (0.86 g/kg b.w). In groups in 
which the effect of insulin and OA was to be examined, glucose load was followed by 
subcutaneous and oral administration of insulin (4 units/kg b.w.) and OA (80 mg/kg b.w), 
respectively. Thereafter blood was collected at 15, 30, 60 and 120 minutes; and blood glucose 
was measured using a glucometer (Accu-Check Perfoma, Roche diagnostics, New Zealand). 
Another OGTT was performed as described above but rats were not starved and were not 
given a glucose load prior to receiving treatment. 
 
2.2.5 Treatment and terminal studies 
 
In the acute study, animals were treated once as indicated in the experimental design. The 
animals were then rapidly sacrificed after 15, 30 and 60 minutes. Immediately after being 
sacrificed, blood samples were collected into thrombin-coated tubes to obtain serum. The rats 
were then quickly dissected to collect epididymal adipose tissue and liver samples which 
were immediately snap frozen in liquid nitrogen and stored at – 20°C. . In sub-chronic study, 
the animals were treated once on a daily basis for 7 and 14 days. These animals were 
sacrificed at the end of the treatment period with blood; adipose and liver tissue being 









Liver samples (8ml/g tissue) were prepared as described by Feres et al. (2010). Samples were 
homogenized in freshly prepared ice-cold buffer ( 100 mM Tris-HCl [pH 7.4], containing1% 
Triton X-100, 100 mM of sodium pyrophosphate, 100 mM of sodium fluoride, 10 mM of 
ethylenediaminetetraacetic acid, 10 mM of sodium orthovanadate, 2.0 mM of 
phenylmethylsulfonyl fluoride, and 3 µg/ ml aprotinin). Insoluble material was removed by 
centrifugation for 20 min at 12 000 x g at 4 °C using Beckman Coulter centrifuge (Avanti J-
26 XPI). The resulting supernatant was collected into eppendorf tubes and kept at - 20 °C for 
further analysis. 
 
2.2.6.2 Adipose tissue 
 
The samples of adipose tissue (100 mg) were prepared as described by Alonso et al. (2005). 
The samples were homogenized at 4°C in 3 ml of lysis buffer (50 mM Tris–HCl ,pH 7.5 
containing 150 mM NaCl, 1% Nonidet P40, 0.05% sodium deoxycholate, 1 mM sodium 
orthovanadate and 3 mM benzamidine). The extracts were centrifuged at 17 418 x g at 4°C 
for 20 min using Beckman coulter centrifuge (Avanti J-26 XPI). There were three layers 
observed after centrifugation; upper fatty layer, middle infranatant and bottom pellet. The 
infranatant was collected into eppendorf tubes and kept at - 20 °C for further analysis. 
 
2.2.7 Western blot analysis 
 
Similar-sized aliquots 40 and 120 µg (liver and adipose tissue) were subjected to reducing 
SDS-PAGE (10% gel). After loading the molecular weight marker (7 µl) and the samples, the 
proteins were subjected to electrophoresis at a voltage of 120 V for 90 minutes. The proteins 
were electro-blotted from the gel onto nitrocellulose membranes for 120 min at 4°C. 
Nonspecific protein binding to the nitrocellulose membranes was reduced by incubating the 
membrane overnight with blocking buffer (1 % BSA in PBS) at 4°C. The primary antibody 
(anti-pAkt Ser473 or anti-HSL ab45422) was diluted 1:1000 in PBS 0.1% tween 20 and 
overlaid on nitrocellulose membrane with shaking for 1 hour at room temperature. Thereafter, 
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the membrane was washed four times for 5 minutes each with PBS 0.1% tween 20. After the 
first washes, a secondary antibody (goat anti-rabbit IgG, dylight 650, Thermo scientific) was 
diluted in PBS 0.1% tween 20 and overlaid on the nitrocellulose membrane with shaking for 
1 hour at room temperature. The membrane was washed four times for 5 minutes with PBS 
0.1% tween 20. The membrane was then rinsed with PBS before viewing and capturing the 
image under fluorescence using a G:BOX-XR5 and Syngene Tools, Vrsn 4.03.00 software 
(Vacutec, S.A.). Western blot analysis of GAPDH protein (loading control) was performed as 
explained above except that 20 µg of liver tissue was loaded. 
 
For phosphorylated HSL (pHSL Ser563), 120 µg of liver was subjected to SDS-PAGE (10% 
gel). Tween buffered saline – tween (TBST) containing 1% BSA was used as a blocking 
agent and to dilute the antibodies. The secondary antibody was anti-rabbit IgG conjugated to 
alkaline phosphatase. The secondary antibody binds specifically to the first antibody and the 
conjugated enzyme allows for detection of the protein of interest on the blot. TBST was used 
to wash the membrane after incubation with the antibodies. A substrate BCIP/NBT solution 
was used to develop colour. After colour had developed, a membrane was washed with water 
prior to capturing the blot image with a G:BOX-XR5. 
 
2.2.8 Hormone sensitive lipase activity assay 
 
2.2.8.1 Liver and adipose tissue homogenization 
 
Hormone sensitive lipase activity assay was performed as described by Ylitalo et al. (2000) 
with minor modifications. Pieces of adipose tissue and liver (200 mg and 8 g, respectively) 
were homogenised in (3 ml and 8 ml) of a 50 mM Tris–HCl (pH 7.5) buffer containing 0.25 
mM sucrose, 1 mM EDTA, 1 mM dithiothreitol and protease inhibitors (10 µg/ml antipain 
and 3 mM benzamidine). The samples were then centrifuged at 17 418 x g at 4°C for 45 min 
using Beckman coulter centrifuge (Avanti J-26 XPI). There were three layers that resulted 
after centrifugation; upper fatty layer, middle infranatant and bottom pellet. The infranatant 







2.2.8.2 Preparation of the substrate solution 
 
To prepare 2.5 ml substrate solution, 1.8 mM cholesteryl[
3
H]oleate (S.A: 2.3 x 10
-3 
Ci/mmol) 
was emulsified with 5.6 mg of phosphatidylcholine/phosphatidylinositol (3/1 by weight) in 
chloroform. Thereafter, 2 ml of 0.1 M potassium phosphate (pH 7) was added and the 
solution was heated to 37°C to allow for evaporation of chloroform. The substrate suspension 
was sonicated 2 times for 2 minutes with 1 minute intervals using a sonic ruptor ultrasonic 
homogenizer (Omni international company, USA) at 40 % power. After the second 
sonication, 0.5 ml of 0.5g/ml BSA in 0.1 M potassium phosphate (pH 7) was added.  
 
2.2.8.3 Activity assay 
 
The activity of lipase was assayed as follows; a 30 µl aliquot of substrate solution was mixed 
with 5 µl of 50 mM EDTA, 5 µl of 5 mM DTT and 100 µl of sample and then incubated for 
2hrs at 20°C with shaking at 100 cycles/min. The reaction was then terminated by addition of 
800 µl of methanol/chloroform/heptane (1.41/1.25/1 by volume) and 250 µl of 0.1 M 
potassium carbonate/0.1 M boric buffer (pH 10.5), and the radioactively labelled oleate was 
recovered by a one-step liquid-liquid partition system. The mixture was shaken vigorously 
for 20 sec and the centrifuged at 800 x g for 20 min. A 250 µl aliquot from the upper phase 
was used for scintillation counting. To 250 µl aliquot 1.8 ml of Fluka liquid scintillation fluid 
counter was added before counting. 
 
2.2.9 Measurement of serum lipids and liver enzymes 
 
The blood samples were left in ice for 2 hours after collection to allow them to clot. 
Thereafter, the samples were centrifuged at 3 000 rpm for 10 minutes to obtain serum using a 
bench centrifuge (Labofuge 200 – Heraeussepatech). Serum was used to determine the levels 
of lipids (Total cholesterol, triacylglycerols and high-density lipoprotein-cholesterol) and 
serum liver enzymes (AST and ALT) using a Labmax Plano Chemistry analyzer (Labtest Av. 
Paulo Ferreira da Costa, 600, Brasilia, Brazil). Low-density lipoprotein (LDL-c) levels were 
calculated using the Friedewald formula: 
 





Principle of total cholesterol assay 
A cholesterol reagent supplies by the manufacturer is used to measure the concentration of 
total cholesterol in a sample. In the reaction, cholesterol esters are hydrolysed by cholesterol 
esterase to yield free cholesterol and fatty acids. An enzyme cholesterol oxidase oxidises free 
cholesterol to cholestene-3-one and hydrogen peroxide. Finally, peroxidase catalyses the 
reaction of hydrogen peroxide with 4-aminoantipyrine and phenol to produce coloured 
quinoneimine product. 
 
Principle of triglyceride assay 
In this assay, a triglyceride reagent is used to measure the concentration of triglyceride in a 
sample. A lipase hydrolyses triacylglycerols in the sample into glycerol and free fatty acids. 
A sequence of three coupled enzymatic steps using glycerol kinase, glycerophosphate 
oxidase, horseradish peroxidase causes the oxidative coupling of 3, 5 dichloro-2-
hydroxybenzenesulfonic acid with 4-aminoantipyrine to form a red quinoneimine dye. 
 
Principle of HDL-c assay 
In the measurement of HDL-c, the samples are first spun to precipitate the cholesterol. HDL 
cholesterol reagent is used to measure concentration of cholesterol in a sample. In the 
reaction, cholesterol esters are hydrolysed by cholesterol esterase to yield free cholesterol and 
fatty acids. An enzyme cholesterol oxidase oxidises free cholesterol to cholestene-3-one and 
hydrogen peroxide. Finally, peroxidase catalyses the reaction of hydrogen peroxide with 4-
aminoantipyrine and phenol to produce coloured quinoneimine product. 
 
Principles of aspartate and alanine aminotransferases assay  
AST: catalyses the transfer of an amino group from L-aspartate to 2-oxoglutarate to form 
oxaloacetate and L-glutamate. The produced oxaloacetate is then quantitatively by the MDH 
– NADH reaction which oxidises NADH. The decrease in absorbance due to the oxidation of 
NADH to NAD is monitored at 340 nm. The rate of decrease in absorbance of the reaction 
mixture is directly proportional to the AST enzyme in the sample 
 
ALT: catalyses the transfer of an amino group from L-alanine to 2-oxoglutarate to form 
pyruvate and L-glutamate. The produced pyruvate is then determined quantitatively by the 
LDH – NADH reaction which oxidises NADH. The decrease in absorbance due to the 
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oxidation of NADH to NAD is monitored at 340 nm. The rate of decrease in absorbance of 
the reaction mixture is directly proportional to the ALT enzyme in the sample. 
 
 
2.2.10 Protein determination 
 
Protein determination was carried out using the biuret method for liver samples and the 
Lowry method for adipose tissue samples. The biuret assay for protein concentration was as 
described by Gornall et al. (1949) with modifications. To 2 ml of sample in a test tube,  3 ml 
of biuret reagent [12 mM copper sulphate pentahydrate (CuSO4.5H2O), 32 mM potassium 
sodium tartrate (NaKC4H4O6.4H2O), and 30 mM potassium iodide (KI) in 0.1 N NaOH] was 
added. The tubes were vortexed before incubation at 37 °C for 10 minutes.  The tubes were 
then allowed to cool and absorbance was read at 540 nm against a blank containing buffer. 
Bovine serum albumin (BSA) of 0 – 100 µg was used to construct a standard curve from 
which protein concentrations of samples were extrapolated.  
 
In adipose tissue, protein concentration was determined by the method of Lowry et al. (1951) 
with BSA as standard (0-100 µg). Samples were diluted using 0.1 N NaOH to 0.5 ml final 
volume, and 5 ml of alkaline reagent  (100 volumes of 4% sodium carbonate in 0.1 N NaOH 
and 4% copper sulphate in 8% of sodium potassium tartrate) were then added and the mixture 
was incubated at 40°C for 15 minutes. The tubes were allowed to cool before adding 0.5 ml 
of Folin Ciocalteu reagent (diluted 1:2 with deionised water). The tubes were left standing at 




2.3 Statistical analysis 
 
All data were expressed as means ± standard error of means (SEM). Statistical analysis was 
done using GraphPadInStat Software (version 5.00, GraphPad Software, San Diego, 
California, USA). Statistical comparison between groups was done using one-way analysis of 
variance (ANOVA) followed by Turkey-Kramer multiple comparison test. Values of p < 0.05 






This chapter presents the results as follows: 
a) Dissolution of OA 
b) Glucose tolerance 
c) Acute studies 
d) Chronic studies 
3.1 Dissolution of OA 
Oleanolic acid suspended better in 50 % DMSO in physiological saline. Therefore, 80 mg/kg 
b.w. of OA suspended with 50 % DMSO in physiological saline was used in subsequent 
studies. 
 
3.2 Oral glucose tolerance test 
The OA treatment did not decrease acute blood glucose levels in rats (Figure 7 below). This 
trend was observed in both starved and non-starved rats. The blood glucose levels started to 
decrease after 15 minutes following insulin treatment in non-starved rats. This decrease 
became significant after 60 minutes in rats that were not starved when compared to diabetic 
controls and OA treated rats. In rats that received glucose, insulin decreased glucose after 15 
minutes and this decrease was only significant after 2 hours when compared to control 
animals and OA treated rats. Treatment of non-starved rats with insulin and OA showed 
blood glucose decrease that was similar to rats treated with insulin only. In starved animals, 
the effect of OA plus insulin was greater than that of treatment with insulin. This difference 
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Figure 7: Acute effect of OA on blood glucose levels in diabetic rats. A: Non-fasted  
rats not given glucose load; B: Fasted rats given glucose load. Values are presented 
as means ±SEM for four rats per group. * p< 0.05 by comparison diabetic control 









3.3 Acute studies 




Figure 8: 10 % reducing SDS-PAGE gels of liver supernatant and adipose tissue infranatant (40 µg and 
120 µg, respectively). Mw = Molecular weight; NC = normal control; DC = diabetic control; NI = normal 
insulin; DI = diabetic insulin; NO = normal OA; DO = diabetic OA; NOI = normal OA + insulin; DOI = 
diabetic OA + insulin. 
The results in Fig 8 show the proteins that were present in liver and adipose tissue after the 
gels were stained with a coomassie stain. There were low proteins in the infranatant of 
adipose tissue when compared to the supernatant of liver tissue. In subsequent studies similar 
gels were prepared and probed with different specific antibodies of interest.  
 
A. Liver 
B. Adipose tissue 
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3.3.2 Expression of AKT and HSL liver and adipose tissue samples 
Two samples from each group were randomly chosen and mixed for western blot analysis. 
3.3.2.1 Effect of OA on phosphorylation of AKT 
 
 
Figure 9: Effect of OA on phosphorylated AKT in liver 15, 30 and 60 minutes following treatment (40 µg 
and 20 µg protein was loaded for p-AKT and GAPDH, respectively). The values from densitometry of p-
AKT were normalised to the levels of GAPDH protein (loading control) and were expressed as the mean-
fold increase. Mw = Molecular weight; NC = normal control; DC = diabetic control; NI = normal insulin; 
DI = diabetic insulin; NO = normal OA; DO = diabetic OA; NOI = normal OA + insulin; DOI = diabetic 




The results of AKT phosphorylation in liver are shown in Fig 9. Fifteen minutes after 
treatment, the expression of phosphorylated AKT was high in diabetic animals treated with 
insulin, normal animals treated with OA plus insulin and in diabetic animals treated with OA 
plus insulin. This trend in AKT phosphorylation was observed 30 minutes after treatment but 
expression levels were lower.  It was not observed in the DOI group in which the AKT band 
is distorted. In all other groups, the expression of phosphorylated AKT was very low. Sixty 
minutes after treatment, phosphorylated AKT expression was elevated in normal animals 
treated with insulin only and in diabetic animals treated with OA plus insulin; there was low 
expression of this protein in other groups. Of note is the gradual decrease in AKT 
phosphorylation in diabetic animals treated with insulin following 15, 30 and 60 minutes of 
treatment. Interestingly, the expression of AKT in diabetic animals treated with OA did not 
show any significant change in all treatment times. 
 
The results of phosphorylation of HSL are shown in Fig 10 below. Fifteen minutes after 
treatment, phosphorylation of HSL was high in normal control animals when compared to 
diabetic control animals. In diabetic rats, expression of phosphorylated HSL decreased 
following treatment with insulin and a slight decrease was observed following treatment with 
OA plus insulin. However, treatment of diabetic rats resulted in an increase in the amount of 
phosphorylated HSL. In normal animals, treatment of animals with insulin and OA plus 
insulin resulted in a slight decrease in the amount of phosphorylated HSL. In normal animals 
treated with OA there is a smeared band which the system could not quantify. Thirty minutes 
after treatment, phosphorylation of HSL was high in normal control animals when compared 
to diabetic control animals. In diabetic rats, the expression of phosphorylated HSL was 
elevated following treatment with insulin whereas in animals treated with OA and OA plus 
insulin smeared bands were observed but could not be quantified by the system. In normal 
animals, treatment with insulin, OA and OA plus insulin resulted in decrease in the 
expression of phosphorylated HSL. Sixty minutes after treatment, phosphorylation of HSL 
was high in normal control animals when compared to diabetic control animals. In diabetic 
animals, expression of phosphorylated HSL was elevated following treatment with insulin 
and OA. However, following treatment with OA plus insulin a reduction in the expression of 
phosphorylated HSL was observed. In normal animals, treatment of animals with insulin 









Figure 10: Effect of OA on phosphorylated HSL in liver following 15, 30 and 60 minutes of treatment 
(120 µg and 20 µg protein was loaded for p-HSL and GAPDH, respectively). The values from 
densitometry of p-HSL were normalised to the levels of GAPDH protein (loading control) and were 
expressed as the mean-fold increase. Mw = Molecular weight; NC = normal control; DC = diabetic 
control; NI = normal insulin; DI = diabetic insulin; NO = normal OA; DO = diabetic OA; NOI = normal 
OA + insulin; DOI = diabetic OA + insulin. On the normalised data, non-diabetic and diabetic animals 
are grouped separately for simplicity. 
However, following treatment of animals with OA and OA plus insulin there was a decrease 




3.4. Sub-chronic studies 






Figure 11: Effect of OA on HSL expression in liver following 7 days of treatment (40 µg and 20 µg protein 
was loaded for HSL and GAPDH, respectively). The values from densitometry of HSL were normalised 
to the levels of GAPDH protein (loading control) and were expressed as the mean-fold increase. NC = 
normal control; DC = diabetic control; NI = normal insulin; DI = diabetic insulin; NO = normal OA; DO 
= diabetic OA; NOI = normal OA + insulin; DOI = diabetic OA + insulin. On the normalised data, non-





The results of HSL expression in liver after 7 days of treatment are shown in Fig 11. There 
were 3 bands of HSL observed in liver tissue after 7 days of treatment (76, 48, 42 kDa). The 
76 kDa isoform was only quantified in three experimental groups: normal control, normal 
animals treated with insulin only and normal animals treated with both insulin and OA. There 
does, however, seem to weak and diffuse bands in other groups. The 48 kDa isoform was 
highly expressed in two experimental groups, normal control and in diabetic animals treated 
with insulin only. In all the other groups, the expression of this isoform was very low. The 
expression of 42 kDa HSL isoform was high in diabetic controls when compared to normal 
controls. However, treatment of normal animals with insulin, OA and insulin plus OA 
increased the expression of this isoform. Treatment of diabetic animals with insulin 
dramatically increased the expression of this isoform while OA treatment caused a slight 
increase in the expression. A combination of OA and insulin seemed to have no effect on the 
expression of this isoform when compared to diabetic control animals.  
 
 
The results of HSL expression in liver after 14 days of treatment are shown in Fig 12 below. 
There were three isoforms of HSL detected (80, 50, 45 kDa) following a 14 day treatment of 
rats. The 80 kDa isoform was highly expressed in the diabetic control animals compared to 
normal control animals after the experimental period. Following 14 day treatment with 
insulin, OA and OA plus insulin expression of this HSL isoform decreased in diabetic 
animals especially in animals treated with insulin only. Treatment of normal animals with 
insulin increased the expression of this isoform of HSL while treatment with OA only 
resulted in a decrease in the expression. Treatment of normal animals with OA plus insulin 
seemed to have no effect on the expression of this isoform. The 50 kDa isoform was 
expressed more in normal controls when compared to diabetic control animals. Treatment of 
normal animals with insulin increased the expression of this isoform whereas treatment of 
normal animals with OA and OA plus insulin decreased its expression. The treatment of 
diabetic animals with insulin decreased the expression while treatment with OA increased the 
expression of this isoform. Insulin plus OA treatment seemed to have no effect. The 
expression of a 45 kDa isoform of HSL was low in both control groups. However, following 
14 day treatment of both normal and diabetic animals had elevated expression of this isoform 








Figure 12: Effect of OA on HSL expression in liver following a 14 day treatment (40 µg and 20 µg protein 
was loaded for HSL and GAPDH, respectively). The values from densitometry of HSL were normalised 
to the levels of GAPDH protein (loading control) and were expressed as the mean-fold increase. Mw = 
Molecular weight; NC = normal control; DC = diabetic control; NI = normal insulin; DI = diabetic 
insulin; NO = normal OA; DO = diabetic OA; NOI = normal OA + insulin; DOI = diabetic OA + insulin. 










Figure 13: Effect of OA on HSL expression in adipose tissue following a 14 day treatment (120 µg protein 
was loaded for both HSL and GAPDH). The values from densitometry of HSL were normalised to the 
levels of GAPDH protein (loading control) and were expressed as the mean-fold increase. Mw = 
Molecular weight; NC = normal control; DC = diabetic control; NI = normal insulin; DI = diabetic 
insulin; NO = normal OA; DO = diabetic OA; NOI = normal OA + insulin; DOI = diabetic OA + insulin. 
On the normalised data, non-diabetic and diabetic animals are grouped separately for simplicity. 
 
The results of HSL expression in adipose tissue are shown in Fig 13. HSL of a molecular 
weight of approximately 86 kDa was detected in adipose tissue following 14 day treatment. 
HSL was highly expressed in diabetic control animals when compared to normal control 
animals. Following treatment of diabetic animals with insulin and OA, the expression of HSL 
decreased and this decrease was more prominent when diabetic animals were treated with OA 
plus insulin. Treatment of normal animals with insulin, OA and OA plus insulin resulted in 










Figure 14: Effect of OA on HSL activity in liver (A) and adipose tissue (B) following a 14 day treatment 
(n= 6 in each group). Values are presented as means ± SEM. p < 0.05 by comparison with normal 
control animals (NC). ♦ p < 0.05 by comparison with diabetic control animals (DC). # p < 0.05 by 
comparing diabetic to normal rats of the same treatment. 
 
Figure 14 shows the results of HSL activity in liver and adipose tissue. In liver, there was no 
significant difference in HSL activity across all treatment groups. However, normal animals 
treated with insulin or oleanolic acid had low HSL activity when compared to normal control 
animals. A combination of insulin plus OA lowered HSL activity further in normal animals. 
In diabetic animals, diabetic control and insulin treated animals seems to have higher HSL 
activity when compared to animals treated with OA and OA plus insulin. Adipose tissue had 
high HSL activity compared to liver. In normal animals, the HSL activity in animals treated 
with insulin plus OA was very high when compared to that in control animals and those 
animals treated with insulin or OA. In diabetic animals, control animals and OA treated 





3.6 Serum lipid profile 
 

































Figure 15: The effects of OA on total cholesterol (TC) levels in normal and diabetic male Sprague-Dawley 
rats following 14 day treatment (n = 6 in each group). Values are presented as means ± SEM. p < 0.05 
by comparison with normal control animals (NC). ♦ p < 0.05 by comparison to diabetic control animals 
(DC). 
 
The levels of total cholesterol were significantly high in diabetic control group when 
compared to normal control group (Fig 15). Following a 14 day treatment of diabetic animals 
with insulin, there was a reduction in levels of total cholesterol even though this was not 
statistically significant. Treatment of diabetic animals with OA and OA plus insulin resulted 
in a significant reduction in total cholesterol levels. Treatment of normal animals seemed to 













































Figure 16: The effects of OA on triacylglycerols (TGA) levels in normal and diabetic male Sprague-
Dawley rats following 14 day treatment (n = 6 in each group). Values are presented as means ± SEM. 
p < 0.05 by comparison with normal control animals (NC). ♦ p < 0.05 by comparison to diabetic control 
animals (DC). # p < 0.05 by comparing diabetic to normal rats of the same treatment. 
 
The levels of triacylglycerols were high in diabetic control animals when compared to normal 
control animals even though this was not statistically significant (Fig 16). Treatment of 
normal animals with insulin, OA and OA plus insulin decreased the levels of triacylglycerols. 
However, treatment of diabetic animals with OA and OA plus insulin significantly elevated 
triacylglycerols while treatment with insulin alone seemed to have no effect. Levels of TGA 













































Figure 17: The effects of OA on HDL-c levels in normal and diabetic male Sprague-Dawley rats following 
14 day treatment (n = 6 in each group). Values are presented as means ± SEM.  
 
There was no statistical difference observed in levels of HDL-c across all groups, but it can 
be seen that in normal animals treated with OA or insulin only, there was a slight decrease 
(15% and 23%, respectively) in levels of HDL-c when compared to normal controls (Fig 17). 
However in normal animals treated with OA plus insulin no change was observed following 
treatment. There was also a slight decrease in HDL-c levels of 9 % and7 % observed in 
diabetic animals treated with insulin and OA plus insulin, respectively and a 2.4 % increase 
in diabetic animals treated with OA when compared to diabetic control group. Treatment with 














































Figure 18: The effects of OA on LDL-c levels in normal and diabetic male Sprague-Dawley rats following 
14 day treatment (n = 6 in each group). Values are presented as means ±SEM.  p < 0.05 by comparison 
with normal control animals (NC). ♦ p < 0.05 by comparison diabetic control animals (DC). # p < 0.05 by 
comparing diabetic to normal rats of the same treatment. 
 
Diabetic control animals had higher levels of LDL-c levels when compared to normal control 
animals. However, following 14 day treatment with insulin, OA and OA plus insulin the 
levels of LDL-c drop significantly to levels of normal control animals (Fig 18). In fact LDL-c 
levels of diabetic animals treated with OA or OA plus insulin are below those in control 
animals. The levels of LDL-c increased following treatment in all treated normal animals and 






3.7 Serum liver enzymes 
 
































Figure 19: The effects of OA on aspartate aminotransferase (AST) levels in normal and diabetic male 
Sprague-Dawley rats following 14 day treatment (n = 6 in each group). Values are presented as means ± 
SEM. p < 0.05 by comparison with normal control animals (NC).  
 
The results of AST levels in serum are shown in Fig 19. The AST levels were high in diabetic 
control group compared to normal control group, and this difference was statistically 
significant. The treatment of both normal and diabetic animals with insulin elevated the levels 
of AST even though this increase was statistically significant in normal animals only. In 
normal animals this elevation of AST levels was also observed in animals treated with OA 
and OA plus insulin but was not as high as that of animals treated with insulin only. 


































Figure 20: The effects of OA on alanine aminotransferase (ALT) levels in normal and diabetic male 
Sprague-Dawley rats following 14 day treatment (n = 6 in each group). Values are presented as means 
±SEM. p < 0.05 by comparison with normal control animals (NC). 
 
The results of ALT levels in serum are shown in Fig 20. The ALT levels were high in 
diabetic control animals when compared to normal control animals and this difference was 
statistically significant. Treatment of normal animals did not have any significant effect on 
ALT levels. However, treatment of diabetic animals with insulin increased ALT levels while 
treatment with OA and OA plus insulin decreased them. The changes of ALT in diabetic 
animals following treatment were not statistically significant. The levels of ALT were 
reduced by 6% and 12% in diabetic animals treated with OA and OA plus insulin when 
compared to diabetic control animals, respectively. Levels of ALT were high in all diabetic 








The aim of this study was to investigate the effect of plant-derived oleanolic acid on insulin 
signalling pathway, lipid profile and serum liver enzymes (aspartate and alanine 
aminotransferase) in streptozotocin-induced diabetic male Spraque-Dawley rats. This study 
was conducted in an effort to better understand the mechanism by which oleanolic acid exerts 
its hypoglycaemic and other metabolic effects in the type 1 diabetic rat model. Streptozotocin 
was used to induce diabetes; this compound is the commonly used diabetogenic agent in both 
insulin-dependent and non-insulin dependent diabetes depending on the dose used and route 
of delivery (Szkudelski, 2001). Streptozotocin enters through glucose transporter GLUT2 
also expressed in pancreatic beta cells where it causes DNA damage and subsequent death of 
beta cells and it has also been reported that it causes production of reactive oxygen species 
(Szkudelski, 2001; Gao et al. 2009). In this study 60 mg/kg b.w. of streptozotocin was used 
to induce type 1 model of diabetes and only animals with ≥18 mmol/L blood glucose after 18 
hours of fasting were used (Refer to fig. 7). The two-hour oral glucose tolerance tests results 
show that OA had no acute effect on blood glucose levels as there was no statistical 
difference observed between diabetic control and OA-treated rats blood glucose levels in both 
fasted and non-fasted rats. Insulin treated rats which acted as positive control showed a 
significant decrease in blood glucose levels after 60 minutes in non-fasted rats. In fasted rats 
given a glucose load, the significant decrease in blood glucose with insulin was only 
observed after 120 minutes. The results from the OGTTs suggest that OA on its own does not 
exert hypoglycaemic effects two hours after its oral administration. When OA was combined 
with insulin in non-fasted animals, it did not have any effect as the results were similar to 
those of treatment with insulin only. However, administration of OA plus insulin to fasted 
rats loaded with glucose significantly decreased blood glucose after 30 minutes when 
compared to rats given insulin only. These findings are in agreement with those of Gao et al. 
(2009) and Zeng et al. (2012) which showed that OA lowers blood glucose levels in the 
presence of insulin. Zeng et al. (2012) also showed that OA does not decrease blood glucose 
in type 1 diabetic rats treated for 2 weeks. These results suggest that OA enhances the effect 




This study also investigated the sub-chronic effect of oleanolic acid on lipid profile (Total 
cholesterol, triacylglycerols, high-density lipoprotein cholesterol and low-density lipoprotein 
cholesterol) following a 14 day daily treatment regime. This was of importance as it has been 
shown that the most common lipid abnormalities in diabetes are associated with increase in 
cholesterol and triacylglycerols; increase  in these lipids leads to development of micro and 
macro vascular complications associated with diabetes (Mitra et al. 1995; Ruzaidi et al. 
2005). The results of this study show that diabetic control animals have high levels of total 
cholesterol when compared to normal control animals. Following treatment, total cholesterol 
decreased in diabetic animals treated with OA and OA plus insulin but remained high in 
diabetic animals treated with insulin only. These results suggest that OA possess anti-
hypercholesterolemic effect in type 1 diabetes. In normal animals, the levels of total 
cholesterol did not change suggesting that treatment of normal animals had no effect on total 
cholesterol. The levels of triacylglycerols were also high in diabetic control animals when 
compared to normal control animals. After treatment of normal animals, the levels of 
triacylglycerols dropped. However, it remained the same in diabetic animals suggesting that 
treatment did not have any effect on diabetic treated animals. de Melo and colleagues (2010) 
have previously reported that OA improves dyslipidemia after high fat diet by decreasing 
total cholesterol and triglyceride levels in normal male Swiss mice. In this study OA also 
decreased the levels of triacylglycerols in normal rats but increased them in diabetic rats. 
However, the opposite was true with total cholesterol in normal animals in which its levels 
increased following treatment with OA in contrast to diabetic animals in which the total 
cholesterol levels dropped significantly. Zeng et al. (2012) have reported that OA lowers 
liver and plasma triacylglycerols in type 2 diabetic rats. However, in this study OA did not 
reduces triglyceride levels in diabetic rats but it did so in normal animals. These findings 
suggest that OA activity requires the presence of insulin. 
 
HDL is responsible for transport of cholesterol from peripheral tissues and subsequent 
transport to the liver through a process known as ‘reverse cholesterol’ transport (Salter and 
Brindley, 1988; Chung and Wasan, 2004). LDLs are lipoproteins which are main carriers of 
unesterified and esterified cholesterol to tissues where they are internalized through the LDL 
receptors (Barakat et al. 1996). In diabetes, levels of HDL-cholesterol are increased and those 
of LDL-cholesterol are increased and this poses a threat in diabetic patients as these changes 
have been associated with development of atherosclerosis (Gao et al. 2009; de Melo et al. 
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2010). In this study, the results showed that diabetic animals had high levels of HDL-c 
compared to normal animals but this difference was not statistically significant. However, the 
levels of HDL-c decreased following treatment with insulin, OA and insulin plus OA. This 
decrease was more prominent in normal animals even though this decrease was not 
statistically significant. The minor changes that were observed could be due to a fact that the 
animals were exposed to treatment for a short period of time. These results suggest that 
treatment for 14 days did not have any significant effect on HDL-c levels. The levels of LDL-
c were higher in diabetic control animals than in normal control animals after 14 days. 
Following treatment of diabetic animals, levels of LDL-c were reduced to levels of normal 
levels. However, treatment of normal animals seemed to increase LDL-c levels even though 
this increase was not statistically significant. These results suggest that treatment for 14 days 
has a positive effect on LDL-c levels only in diabetic animals. Studies done on type 2 
diabetic animals have shown that OA improves lipid profile in diabetic rats by decreasing 
total cholesterol, LDL-c and TGA and increasing HDL-c levels (Gao et al. 2009; de Melo et 
al. 2010) 
 
This study also had acute experiments to investigate the effects of OA on phosphorylation of 
enzymes involved in the insulin signalling pathway such as AKT and HSL. Protein kinase 
B/AKT is a central protein in the insulin signalling pathway and it is activated by 
phosphatidyl-4, 5-bisphosphate in response to binding of exogenous growth factors such as 
insulin to cell surface receptors (Shtilbans et al. 2008). The results of this study show that 
after 15 and 30 minutes of treatment the expression of phosphorylated AKT was high in 
diabetic animals treated with insulin only, normal animals treated with OA plus insulin and 
diabetic animals treated with OA plus insulin. After treating the animals for 60 minutes, 
expression of phosphorylated AKT was high in normal animals treated with insulin only and, 
normal and diabetic animals treated with OA plus insulin. These results suggest that when 
diabetic animals are treated with insulin they are more sensitive when compared to normal 
animals which only showed a significant response after 60 minutes of treatment. Since 
diabetic animals lack insulin, administration of it causes a quick response as there will be 
elevated levels of glucose in the blood. However, in normal animals there will be normal 
levels if glucose and insulin in the blood therefore administration of insulin will not cause 
much change as it does in diabetic animals. The increased sensitivity in diabetic rats could be 
due to increase in insulin receptors on insulin dependent cells, as there will be little or no 
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glucose within the cells. In normal animals treated with OA, there was a lower amount of 
phosphorylated AKT suggesting that OA on its own has little effect on AKT phosphorylation. 
However, in diabetic animals treated with OA only there was low expression of 
phosphorylated AKT. Interestingly, after 15 and 30 minutes following treatment there was 
very low expression of phosphorylated AKT in normal animals treated with insulin only, high 
expression was only observed in normal animals treated with OA plus insulin and a similar 
trend was observed with diabetic animal after 60 minutes of treatment. These results suggest 
that OA does have enhancement effect on phosphorylated AKT when used in combination 
with insulin. These findings are in agreement with those of Zeng and colleagues (2012) who 
showed that OA increases expression of AKT in liver tissue in type 2 diabetic animals. Other 
pentacyclic triterpenoids have been shown to stimulate insulin-mediated tyrosine 
phosphorylation in 3T3-L1 adipocytes (Jung et al. 2007). 
 
This study also aimed in investigating the effect of OA on phosphorylated levels of hormone 
sensitive lipase (p-HSL) after 15, 30 and 60 minutes after treatment. This was done to 
investigate whether OA mimics the activity of insulin which suppresses or dephosphorylates 
HSL thus inhibiting lipolysis. The HSL isoforms that have been reported have a molecular 
weight ranging from 84 – 130 kDa but in this study a 200 kDa band was detected in a 
phosphorylated state of HSL. It is possible that phosphorylated HSL dimerises and bind to a 
fatty acid binding protein (Krintel, 2010). Shen and colleagues (2000) have shown that an 84 
kDa HSL isoform dimerises into a 160 kDa fragment in a phosphorylated state. Diabetes 
mellitus is accompanied with increased lipolysis in adipose tissue due to lack of insulin, this 
is followed by elevated levels of serum free fatty acids (FFA) and subsequent increased 
gluconeogenesis in the liver (Clause et al. 2005; Nishino et al. 2007). The elevated levels of 
FFAs induce insulin resistance in insulin sensitive tissues. Thus inhibition of FFAs release 
may result in amelioration of diabetes (Voshol et al. 2003; Nishon et al. 2007). Treatment of 
normal animals with insulin resulted in decrease in pHSL levels after 15 and 30 minutes of 
treatment; and this decrease in phosphorylation was reversed after 60 minutes of treatment 
when compared to control animals. However, treatment of diabetic animals resulted in 
decrease in pHSL levels after 15 minutes but after 30 and 60 minutes of treatment the 
phosphorylation of HSL increased. These observations suggest that insulin on its own 
suppress the phosphorylation of HSL after 15 and 30 minutes following treatment of normal 
animals with OA only, there was no pHSL observed. After 15 and 30 minutes following 
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treatment some of the bands were smeared and were not detected by the system for 
quantification. However, after 60 minutes following treatment all bands were visible and 
were quantified, thus giving a clear indication of treatment on the expression of 
phosphorylated HSL. In normal animals, treatment with insulin seems to have no significant 
effect whereas treatment with OA and OA plus insulin reduced the levels of phosphorylated 
levels of HSL. In diabetic animals, treatment with insulin and OA slightly increased the 
levels of phosphorylated HSL and the combination of OA plus insulin reduced levels of 
phosphorylated HSL. These results suggest that OA in combination with insulin may reduce 
HSL phosphorylation. 
 
In this study, effect of OA was also investigated on expression and activity of HSL in liver 
and adipose tissue after a 14 day daily treatment regime. HSL has been reported to be the key 
enzyme which regulates the most essential energy source and this enzyme is present in many 
tissues such as: adipose, heart, pancreatic beta cells and liver (Lampidonis et al. 2011). HSL 
in various tissues has been shown to hydrolyse a variety of carboxyl esters (Quiroga and 
Lehner, 2012). Streptozotocin-induced diabetes has been shown to cause a two-fold increase 
in HSL activity in adipose tissue and this change in activity parallels with an increase in HSL 
mRNA and HSL immunoreactive protein (Sztalryd and Kraemer, 1995). The results of this 
study also showed that untreated STZ induced diabetic rats had increased HSL expression 
when compared to normal untreated rats after 14 days of treatment. Unsurprisingly, treatment 
of diabetic animals with insulin resulted in a decrease in HSL expression and activity in 
adipose tissue. These results were in agreement with those of Sztalryd and Kraemer (1995) 
who showed that insulin treatment inhibits or decreases lipolysis in adipose tissue. In adipose 
tissue, treatment of normal animals with insulin, OA and OA plus insulin resulted in an 
increase in HSL expression but the activity of the enzyme was decreased except for animals 
treated with OA plus insulin. OA treatment caused a decrease in HSL expression and activity 
of the enzyme in diabetic animals. Insulin and OA treatment reduced both expression and 
activity of HSL; this suggests that OA enhances the activity of insulin. The results of this 
study suggest that OA plus insulin does inhibit lipolysis in STZ-induced diabetes in adipose 




There has been three HSL isoforms that have been reported with molecular weight ranging 
from 84 – 130 kDa (Holm, 2003) and indeed in adipose tissue the HSL that was detected in 
this study ranged from 80 – 100 kDa. However, Langfort and colleagues (1999) reported 
HSL with a molecular weight of 55 kDa in muscle. In this study; three isoforms of HSL with 
molecular weight of approximately 76, 48 and 42 kDa were detected in the liver. Very little 
has been reported on HSL in the liver but some studies have shown that deficiency of HSL in 
liver causes cholesterol ester accumulation which leads to decreased cholesterol ester 
hydrolase activity (Sekiya et al. 2008). This indicates that HSL plays a major role in the liver. 
A 76 kDa isoform of HSL was only expressed in control normal animals and normal animals 
treated with insulin and OA plus insulin. The 48 kDa isoform was highly expressed in normal 
control animals when compared to diabetic control. Following 7 day treatment, in normal 
animals the expression of this isoform decreased. However, treatment of diabetic animals 
resulted in the increased expression of this isoform and this increase was more prominent in 
animals treated with insulin only. The 42 kDa isoform was highly expressed in diabetic 
control animals when compared to normal control animals. Treatment of both normal and 
diabetic animals resulted in an increase in the expression of this isoform and this increase was 
more pronounced in diabetic animals treated with insulin only. 
 
The effect of OA on the expression of HSL was also investigated in liver tissue after 14 days 
treatment. The three isoforms observed after 7 days of treatment were also observed after 14 
days of treatment. However, the approximate molecular weights of these isoforms were a 
slightly higher than what there were at 7 days (45, 50 and 80 kDa) and this could be 
attributable to experimental variation. In this study, an 80 kDa isoform was highly expressed 
in diabetic control animals compared to normal animals which suggest that this isoform 
mainly functions to hydrolyse triacylglycerols. All treated diabetic animals showed a 
decrease in the expression of this isoform suggesting that OA does have an inhibitory effect 
on HSL. Interestingly, in normal animals a decrease in expression was observed only in 
animals treated with OA. An increase in animals treated with insulin was observed whilst no 
change was seen in OA plus insulin treatment group. The 50 kDa isoform seemed to be 
expressed constantly across all experimental groups. The expression of a 45 kDa isoform was 
low in both control animal groups. Following treatment, the expression of this isoform was 
elevated in all animal groups with greater effects observed in normal animals and more so in 
normal animals treated with OA plus insulin. This isoform may be associated with hydrolysis 
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of cholesterol esters that has been reported in liver. Interestingly, the increase in the 
expression of a 45 kDa isoform of HSL parallels with an increase in HDL-c in treated 
diabetic animals which also suggest that this isoform may be responsible for hydrolysis of 
cholesterol esters in the liver. After 14 days of treatment, the effect of OA was also assessed 
on the activity of HSL. In normal animals HSL activity was high in control animals and those 
treated with insulin and OA whereas a reduction in activity was observed in animals treated 
with OA plus insulin. In diabetic animals, HSL activity was high in control and insulin 
treated animals when compared to OA and OA plus insulin treated animals. These results on 
HSL activity further show that OA does enhance the activity of insulin as both normal and 
diabetic animals treated with OA plus insulin showed a reduction in HSL activity in liver. 
 
Diabetes has been shown to induce liver damage as evidenced by increase in levels of serum 
aminotransferases in diabetic rats (Gao et al. 2009). In diabetes, the elevated levels of 
circulating glucose results in production of free radicals (Al-Faris et al. 2010). These radicals 
are generated by glycosylation of proteins and oxidation of glucose. Free radicals also exert 
cytotoxic effects on cellular lipids and this tissue damage has been observed in the 
development of diabetes mellitus (Lee, 2006). The results of this study demonstrate that in 
untreated diabetic animals levels of both AST and ALT are elevated when compared to 
untreated normal animals as has been reported in other studies (Jeong, 1999; Gao et al. 2009). 
Following treatment of diabetic animals for 14 days, there was a decrease in levels of AST 
and ALT in animals treated with OA and OA plus insulin. This suggests that OA possess 
hepatoprotective effect as has been reported by other researchers (Liu, 1995; Jeong, 1999; 
Gao et al. 2009). In diabetic animals that were treated with insulin only, the levels of AST 
and ALT increased. Interestingly, there has been a reported case of a 45 year old man who 
was diagnosed with type 2 diabetes and his aminotransferases began to increase after starting 
insulin treatment (Tawata et al. 2000). Even in normal animals, treatment with insulin 
significantly elevated the levels of AST but the levels of ALT did not change. However, 
treatment with OA and OA plus insulin did not have any effects on AST and ALT levels in 
normal animals. These results suggest that OA does have hepatoprotective properties as it 
reduces AST and ALT levels that were elevated in diabetic animals. The reduction of these 
aminotransferases was more prominent in animals treated with both insulin and OA, 
suggesting that insulin enhances the activity OA. The results of this study indicate that OA in 
absence of insulin can increase phosphorylation of AKT and decrease expression of HSL in 
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liver and adipose tissue in diabetic rats. OA can improve lipid profile in diabetic rats as it 






The results that were obtained from this study suggest that OA does not possess 
hypoglycaemic effect two hours following administration but does enhance the 
hypoglycaemic effect of insulin. OA improves the lipid profile as it reduces total cholesterol 
and TGA levels; OA also protects liver from damage as it reduces AST and ALT levels in 
serum. The activity of OA involves phosphorylation of AKT. OA has the ability to decrease 
the expression and activity of HSL in liver and adipose tissue. OA may reduce the risk of 
developing cardiovascular complications associated with diabetes and may be a potential 
drug for the management of type 2 diabetes as its enhances the activity of insulin. 
 
5.1 Limitations and future studies 
The limitations to this study were that the effect OA was only investigated on AKT and HSL 
protein of the insulin signalling pathway. Future studies should also investigate protein such 
as PDE3B and PKA as they are in between AKT and HSL in the insulin signalling pathway, 
as the activity of HSL may be affected by other hormones such as adrenaline and glucagon. 
Future studies should include chronic studies to investigate the long term effect of OA on 
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Appendix 1: Biuret and Lowry assay standard curve 
 
 
 
 
 
 
 
